Mode
Text Size
Log in / Sign up

Dihydromyricetin reduces hepatic lipids and improves metabolic markers in murine MASLD modelsA Simple Tea Ingredient Could Help Your Liver

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret preclinical DHM findings cautiously due to heterogeneity and lack of human data.

This preclinical systematic review and meta-analysis included 14 controlled murine studies using diet-induced models of metabolic dysfunction-associated steatotic liver disease (MASLD)/NAFLD. The intervention was dihydromyricetin (DHM) monotherapy compared to high-fat diet controls, with primary outcomes of hepatic triglycerides and total cholesterol, and secondary outcomes including liver enzymes, body weight, serum lipids, glucose homeostasis, antioxidant defenses, malondialdehyde, inflammatory markers, and pAMPK/AMPK ratio. Main results, based on standardized mean differences (SMDs) with 95% confidence intervals, showed reductions in hepatic triglycerides and total cholesterol, improvements in liver enzymes (ALT, AST, ALP), decreases in body weight and liver index, lower serum total cholesterol and LDL, higher HDL, lower fasting glucose and insulin, increased antioxidant defenses (SOD, CAT, GSH, GSH-Px), reduced malondialdehyde, decreased inflammatory markers (TNF-α and IL-6), and an increased pAMPK/AMPK ratio; absolute numbers were not reported. Safety and tolerability were not reported. Key limitations include moderate to high heterogeneity for several outcomes, variability due to differences in study design, and differences in dose and treatment duration. Practice relevance is restrained as more standardized preclinical designs and well-controlled nutraceutical/clinical studies are needed to define clinically relevant, bioavailable dosing and efficacy in humans.

Imagine waking up with a heavy feeling in your stomach. You worry about your liver health, but the doctors just say, "Eat better and exercise more." It feels like advice everyone gives, but it is hard to follow when you are tired or stressed.

Now, scientists have found a potential helper in a common food.

Metabolic dysfunction–associated steatotic liver disease, or MASLD, is a new name for what we used to call fatty liver disease. This condition happens when too much fat builds up in your liver.

It is very common. Many people have it without knowing. The fat makes the liver work harder and can lead to serious problems later.

Current advice focuses on diet and exercise. But many people struggle to make these changes stick. They need something extra to help their bodies heal.

The surprising shift

For years, researchers looked at expensive drugs or complex supplements. They wanted to find a safe way to protect the liver.

But here is the twist. A simple plant compound called dihydromyricetin, or DHM, might be the answer. This substance comes from tea and other plants.

Previous studies showed promise, but no one had looked at all the data together. That changed recently.

What scientists didn't expect

DHM works like a master key. Your cells have locks that control fat storage and inflammation. DHM fits into these locks and turns them on.

Think of your liver as a busy kitchen. Fat is like a pile of dirty dishes piling up. Inflammation is like smoke filling the air.

DHM acts like a super-cleaning crew. It clears the dishes and puts out the smoke. It also helps your body use sugar better so it does not turn into fat.

The study snapshot

Researchers looked at fourteen studies involving mice. These mice ate a high-fat diet to mimic human fatty liver disease.

They gave some mice DHM and left others on the high-fat diet alone. They watched how the mice's livers, blood, and bodies changed over time.

The goal was to see if DHM could fix the damage caused by the bad diet.

The results were clear. Mice taking DHM had less fat in their livers. Their liver enzymes, which signal damage, went down.

Their blood sugar levels improved. They also had better cholesterol numbers. Total bad cholesterol dropped, and good cholesterol went up.

The mice also weighed less. Their bodies produced more antioxidants to fight damage. Inflammation markers in their blood dropped significantly.

In short, DHM helped the mice's bodies handle fat and sugar much better than the control group.

But there's a catch

This is where things get interesting. The study was done on mice. Mice are not humans.

What works perfectly in a mouse might not work the same in a person. The dose given to mice is often much higher than what a human could safely eat.

This doesn't mean this treatment is available yet.

We cannot buy DHM as a cure for fatty liver disease at your local pharmacy today. It is still in the research phase.

If you have fatty liver disease, talk to your doctor. Do not stop your current treatment to try a new supplement.

However, you can look at your diet. Foods rich in flavonoids, like green tea, are generally healthy. They might offer small benefits on their own.

The hope is that scientists will figure out the right dose for humans soon. Until then, focus on the basics: eat well and move your body.

Scientists need to run more tests. They must prove that DHM works safely in people. They also need to find the right amount to take.

This process takes time. It ensures that any new treatment is safe and effective for everyone.

We are closer than ever to having new tools to fight fatty liver disease. Stay informed and keep asking questions about your health.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Dihydromyricetin (DHM) is a food-derived flavonoid widely investigated as a nutraceutical candidate for metabolic dysfunction–associated steatotic liver disease (MASLD) in preclinical models; however, its overall efficacy in diet-induced MASLD/NAFLD models has not been systematically quantified. This PRISMA 2020 systematic review and meta-analysis was registered in PROSPERO (CRD420251119087). PubMed, Embase, Web of Science Core Collection, the Cochrane Library, and four major Chinese databases were searched from inception to December 15, 2025. Controlled murine studies comparing DHM monotherapy with high-fat diet controls were included. Random-effects meta-analyses pooled standardized mean differences (SMDs) with 95% confidence intervals; risk of bias was assessed using SYRCLE’s tool. Fourteen controlled studies were included. Compared with controls, DHM reduced hepatic triglycerides and total cholesterol, improved liver enzymes (ALT, AST, ALP), and decreased body weight and liver index. DHM improved serum lipid profiles (lower total cholesterol and LDL; higher HDL) and glucose homeostasis (lower fasting glucose and insulin). Antioxidant defenses increased (SOD, CAT, GSH, GSH-Px) with reduced malondialdehyde, while inflammatory markers (TNF-α and IL-6) decreased. At the signaling level, DHM increased the pAMPK/AMPK ratio. Heterogeneity was moderate to high for several outcomes, partly explained by dose and treatment duration. In murine diet-induced MASLD/NAFLD models, DHM shows promising multidomain benefits across various physiological outcomes, though some variability remains due to differences in study design. More standardized preclinical designs and well-controlled nutraceutical/clinical studies are needed to define clinically relevant, bioavailable dosing and efficacy. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251119087, PROSPERO, Identifier CRD420251119087.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.